Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Merz Therapeutics GmbH
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07018700CT.gov A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine | — | Recruiting | — | — | — |
NCT07018713CT.gov A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Migraine Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Xeomin® (this asset) | Merz Therapeutics GmbH | P3 | B · 60 |
| Atogepant | Stanford University | P4 | A |
| Zolmitriptan | Zosano Pharma Corporation | P4 | A |
| Naproxen | IRCCS San Raffaele Roma | P4 | A |
| Rizatriptan | Antonios Likourezos | P4 | A |
| Dfn-11 (Sumatriptan Injection) | IRCCS San Raffaele Roma | P4 | BBB |
| Ubrogepant | H. Lundbeck A/S | P4 | BBB |
| Eptinezumab | Stanford University | P4 | BBB |
| Eletriptan | Boehringer Ingelheim | P4 | BBB |
+42 more in the Migraine Disorder cohort
Other indications for Xeomin®
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Stroke Disorder | — | P4 | BB · 70 |
| Chronic Pain Syndrome | — | P3 | B · 60 |
| Primary Dysmenorrhea | — | P3 | NR |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Xeomin® in Migraine Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/xeomin-migraine-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →